Tiziana Life Sciences’ Intranasal Foralumab MSA Trial Highlighted in Late-Breaking Poster at 7th World Parkinson Congress
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Tiziana Life Sciences ( (TLSA) ) is now available.
On April 14, 2026, Tiziana Life Sciences announced that a late-breaking poster on its Phase 2a study of intranasal foralumab in Multiple System Atrophy (MSA) has been accepted for presentation at the 7th World Parkinson Congress, to be held May 24–27, 2026, in Phoenix, Arizona. The poster will detail the design and scientific rationale of the ongoing TILS-025 trial, the first clinical investigation of intranasal anti-CD3 therapy in MSA.
MSA is a rapidly progressive neurodegenerative disorder with no approved disease-modifying treatments, and Tiziana’s trial is testing whether intranasal foralumab can attenuate microglial activation, a recognized driver of disease progression. The open-label Phase 2a study is enrolling up to 10 patients aged 30–85 with clinically established or probable MSA, tracking changes in microglial activation via TSPO PET imaging, clinical scores, brain atrophy, autonomic function, quality of life, and immune biomarkers.
Tiziana’s leadership framed the late-breaking acceptance as evidence of growing interest in its intranasal approach to modulating neuroinflammation within the Parkinson’s and MSA research communities. The visibility at a major international congress may strengthen the company’s scientific profile and support its strategy of positioning foralumab as a novel immunomodulatory therapy across multiple neuroinflammatory and neurodegenerative indications.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on developing breakthrough immunotherapies using alternative drug delivery technologies, particularly intranasal administration. Its lead product candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development and targets neuroinflammatory and neurodegenerative diseases, including non-active secondary progressive multiple sclerosis and other central nervous system disorders.
The company’s platform aims to improve efficacy, safety, and tolerability versus traditional intravenous delivery and is protected by issued and pending patents, positioning Tiziana to build a broader pipeline around nasal immunomodulation strategies.
Average Trading Volume: 195,737
Technical Sentiment Signal: Sell
Current Market Cap: $140.2M
For detailed information about TLSA stock, go to TipRanks’ Stock Analysis page.
